 | | Vol. 12.47 – 30 November, 2021 |
| |
|
|
| Investigators showed that mice with erythroid-specific deletion of all four Sec23 alleles died in mid-embryogenesis with features of congenital dyserythropoietic anemia type II, and that mice with deletion of three Sec23 alleles exhibited a milder erythroid defect.
[Science Advances] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported that bone marrow (BM) vascular endothelial cells secreted semaphorin 3 A (SEMA3A) in response to myeloablation and SEMA3A induced p53–mediated apoptosis in BM endothelial cells via signaling through its receptor, Neuropilin 1 (NRP1), and activation of cyclin dependent kinase 5.
[Nature Communications] |
|
|
|
| Scientists identified Quinacrine (QC) as a sensitizer for Cytarabine (AraC) in treating acute lymphoblastic leukemia (ALL) and showed that QC enhanced AraC-mediated killing of ALL cells, and subsequently abrogated AraC resistance both in vitro and in an ALL-xenograft model.
[Nature Communications] |
|
|
|
| The authors reported the development of an acute myeloid leukemia cell membrane-coated nanoparticle vaccine platform, in which immune-stimulatory adjuvant-loaded nanoparticles were coated with leukemic cell membrane material.
[Leukemia] |
|
|
|
| Analysis of RNA sequencing data, including publicly available datasets, indicated that macrophage fragmentation was a general phenomenon that confounded bulk and single-cell analysis of disaggregated hematopoietic tissues.
[Cell Reports] |
|
|
|
| Using combined integrated analyses of global miRNA expression profiling and state-of-the-art genomic analyses of chromatin such as ChIRP-seq, ChIP-seq, and ATAC-seq, researchers found that some miRNA genes were directly controlled by HOTTIP.
[Oncogene] |
|
|
|
| The authors indicated that Cebpa-enhancer deletion caused cell autonomous neutropenia, which reprogramed and disturbed the quiescence of HSCs, leading to a systemic impairment of the hematopoietic process.
[Blood Advances] |
|
|
|
| Scientists revealed a lymphoid TBX-code and used it to identify an aberrant network around deregulated T-box gene TBX3 in Hodgkin lymphoma which promoted hallmark aberrations of this disease.
[PLoS One] |
| |
|
|
| The authors analyzed whole-exome sequencing data from 1,958 lung cancer cases and controls. Potential clonal hematopoiesis mutations were identified by a set of hierarchical filtering criteria in different exonic regions.
[Cancer Research] |
|
|
|
| To gain a deeper understanding of the molecular characteristics associated with CAR T cell differentiation, researchers performed longitudinal genome-wide DNA methylation profiling of CD8+ CD19-CAR T cells post-infusion in acute lymphoblastic leukemia patients.
[Cell Reports] |
|
|
|
| Scientists reported results of a phase Ib dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory diffuse large B cell lymphoma.
[Blood Advances] |
|
|
|
|
| The authors outline HSC niche biology, review the role of the different classes of extracellular matrix molecules in the niche, and discuss matrix remodeling and the emerging importance of biophysics in HSC niche function.
[Advanced Drug Delivery Reviews] |
|
|
|
| Investigators summarize the available literature regarding immunoPET in imaging hematological malignancies and highlight the pros and cons of current conjugation strategies, and modular chemistry that can be leveraged to develop novel immunoPET probes for hematological malignancies.
[Drug Discovery Today] |
|
|
|
| Scientists discuss in detail the mechanisms involved in the accumulation of cadmium in particular cell lines of the bone marrow and the consequent occurrence of acute myeloid leukemia.
[Leukemia Research] |
|
|
|
|
| An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.
[News Medical Life Sciences] |
|
|
|
| Kura Oncology, Inc. announced that the US FDA has placed the KOMET-001 Phase Ib study of KO-539 in patients with relapsed or refractory acute myeloid leukemia on a partial clinical hold following the company’s recent report of a Grade 5 serious adverse event potentially associated with differentiation syndrome.
[Kura Oncology, Inc.] |
|
|
|
|
| January 16 – 20, 2022
Banff, Alberta, Canada |
|
|
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
